Scinai Immunotherapeutics Enters Financing Agreements for About $4 Million

Scinai Immunotherapeutics (SCNI) entered financing agreements for approximately $4 million in gross proceeds, combining American depositary shares or pre-funded warrants with warrants for additional shares. The agreements cover 2.46 million American depositary shares (ADSs) or pre-funded warrants. Series A-1 warrants give holders the right to purchase up to 3.69 million more ADSs. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.